Abstract | PURPOSE OF REVIEW: RECENT FINDINGS: In recent years studies have uncovered a role for central neurotransmitters in control of the lower urinary tract and specific targets for pharmacological intervention have been identified. Duloxetine inhibits presynaptic neuron reuptake of serotonin and norepinephrine, in the sacral spinal cord, increasing urethral closure forces and thereby reducing episodes of stress urinary incontinence. In clinical trials in women with stress urinary incontinence, duloxetine has demonstrated efficacy in reducing incontinence episodes and increasing quality of life with no serious adverse effects. Nausea was the most common adverse event, being reported as mild-to moderate in severity and transient in most of patients. SUMMARY:
|
Authors | David Castro-Diaz, Maria Antonia Pascual Amoros |
Journal | Current opinion in urology
(Curr Opin Urol)
Vol. 15
Issue 4
Pg. 227-30
(Jul 2005)
ISSN: 0963-0643 [Print] United States |
PMID | 15928510
(Publication Type: Journal Article, Review)
|
Chemical References |
- Adrenergic Agonists
- Serotonin Uptake Inhibitors
- Thiophenes
- Duloxetine Hydrochloride
|
Topics |
- Adrenergic Agonists
(pharmacology, therapeutic use)
- Duloxetine Hydrochloride
- Estrogen Replacement Therapy
- Female
- Humans
- Quality of Life
- Selective Serotonin Reuptake Inhibitors
(pharmacology, therapeutic use)
- Thiophenes
(pharmacology, therapeutic use)
- Urethra
(drug effects, physiopathology)
- Urinary Incontinence, Stress
(drug therapy)
- Urination
(drug effects)
|